Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Aquestive Therapeutics Inc

Healthcare US AQST

4.72USD
0.01(0.21%)

Last update at 2026-06-22T20:00:00Z

Day Range

4.684.91
LowHigh

52 Week Range

2.127.55
LowHigh

Fundamentals

  • Previous Close 4.71
  • Market Cap529.68M
  • Volume1912655
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-70.47700M
  • Revenue TTM44.55M
  • Revenue Per Share TTM0.42
  • Gross Profit TTM 25.99M
  • Diluted EPS TTM-0.78

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -83.78400M -44.15100M -7.62500M -54.41000M -70.53900M
Minority interest - - - - -
Net income -83.78400M -44.13700M -7.87000M -60.20200M -90.03600M
Selling general administrative 79.85M 50.18M 31.75M 52.88M 53.48M
Selling and marketing expenses - - - - -
Gross profit 25.99M 39.69M 29.75M 28.29M 35.84M
Reconciled depreciation 0.55M 0.72M 1.34M 2.39M 2.96M
Ebit -71.05100M -27.33400M -0.16300M -42.06600M -34.67900M
Ebitda -70.49200M -26.61600M 1.18M -41.96700M -34.25600M
Depreciation and amortization 0.56M 0.72M 1.34M 0.10M 0.42M
Non operating income net other - - - - -13.39900M
Operating income -71.05100M -30.77100M -15.10200M -42.06600M -34.67900M
Other operating expenses 115.60M 88.33M 65.69M 89.75M 85.51M
Interest expense 17.10M 16.82M 7.46M 12.44M 22.46M
Tax provision 0.00000M -0.01400M 0.24M 0.00000M 0.00000M
Interest income 4.37M 3.44M 16.32M 0.10M 0.42M
Net interest income -12.73300M -13.38000M 8.86M -12.34400M -22.03800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.01400M 0.24M 5.79M 19.50M
Total revenue 44.55M 57.56M 50.58M 47.68M 50.83M
Total operating expenses 97.04M 70.46M 44.85M 70.36M 70.52M
Cost of revenue 18.55M 17.87M 20.83M 19.39M 14.99M
Total other income expense net -12.73300M -13.38000M 7.48M -12.34400M -35.86000M
Discontinued operations - - - - -
Net income from continuing ops -83.78400M -44.13700M -7.87000M -54.41000M -70.53900M
Net income applicable to common shares - - - -54.41000M -70.53900M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 160.43M 101.42M 57.42M 55.67M 61.99M
Intangible assets - - 1.28M 1.44M 0.05M
Earning assets - - - - -
Other current assets 4.17M 3.29M 1.85M 2.13M 3.08M
Total liab 194.09M 161.58M 163.91M 174.23M 144.13M
Total stockholder equity -33.66200M -60.15600M -106.48700M -118.55400M -82.13400M
Deferred long term liab - - - - -
Other current liab 5.03M 6.63M 5.48M 9.11M 9.96M
Common stock 0.12M 0.09M 0.07M 0.06M 0.04M
Capital stock 0.12M 0.09M 0.07M 0.06M 0.04M
Retained earnings -446.99800M -363.21400M -319.07700M -311.20700M -256.79600M
Other liab - - - 97.56M 68.67M
Good will - - - - -
Other assets - - 0.00000M 6.45M 6.90M
Cash 121.17M 71.55M 23.87M 27.27M 28.02M
Cash and equivalents - - - - -
Total current liabilities 47.61M 18.86M 18.31M 39.68M 21.96M
Current deferred revenue 1.09M 1.05M 1.55M 1.51M 0.77M
Net debt 10.28M -33.54200M 74.95M 28.82M 28.40M
Short term debt 11.62M 0.54M 2.35M 19.11M 2.92M
Short long term debt 9.99M 0.03M 0.02M 18.70M 2.02M
Short long term debt total 131.44M 38.00M 98.82M 56.09M 56.42M
Other stockholder equity 413.21M 302.97M 212.52M 192.60M 174.62M
Property plant equipment - - - 7.90M 5.05M
Total current assets 149.27M 88.22M 40.97M 39.89M 47.26M
Long term investments - - - - -
Net tangible assets - - - -119.98900M -82.18500M
Short term investments - - - - -
Net receivables 17.76M 7.34M 8.47M 4.70M 12.12M
Long term debt 27.52M 32.50M 27.51M 33.45M 51.55M
Inventory 6.17M 6.04M 6.77M 5.78M 4.04M
Accounts payable 29.86M 10.29M 8.93M 9.95M 8.31M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - 0.04M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -256.79600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.64M 1.22M 1.44M 6.45M 6.90M
Deferred long term asset charges - - - - -
Non current assets total 11.16M 13.20M 16.45M 15.79M 14.73M
Capital lease obligations 4.97M 5.48M 5.79M 3.94M 2.85M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -0.15900M -0.99500M -2.52400M -0.91300M
Change to liabilities - - - 1.63M 3.94M
Total cashflows from investing activities -0.56200M -0.15900M -0.99500M - -0.91300M
Net borrowings -0.02600M -0.02300M -22.48700M - -
Total cash from financing activities 102.62M 83.59M 3.97M 11.56M 30.11M
Change to operating activities - - - -0.27800M 1.26M
Net income -83.78400M -44.13700M -7.87000M -54.41000M -70.53900M
Change in cash 49.62M 47.67M -3.40100M -0.75100M -3.78300M
Begin period cash flow 71.55M 23.87M 27.27M 28.02M 31.81M
End period cash flow 121.17M 71.55M 23.87M 27.27M 28.02M
Total cash from operating activities -52.43200M -35.75900M -6.38000M -9.78900M -32.97900M
Issuance of capital stock 100.65M 83.76M 8.91M 13.56M 29.78M
Depreciation 0.55M 0.72M 1.34M 2.39M 2.96M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -0.12600M 0.72M -0.98900M -1.74300M -1.57700M
Change to account receivables -10.37200M 1.09M -3.07300M - -4.93900M
Sale purchase of stock - - -0.01100M - 30.12M
Other cashflows from financing activities -0.81000M -0.14200M 15.45M 0.03M 0.33M
Change to netincome - - - - 20.34M
Capital expenditures 0.56M 0.16M 0.99M 2.52M 0.91M
Change receivables - - - - -5.35300M
Cash flows other operating - - - - 13.51M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -3.78300M
Change in working capital 12.18M -9.95700M -5.34100M 32.01M -1.73000M
Stock based compensation 7.62M 7.10M 2.69M 4.38M 6.82M
Other non cash items 11.00M 10.52M 2.80M 5.85M 15.69M
Free cash flow -52.99400M -35.91800M -7.37500M -12.31300M -33.89200M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
AQST
Aquestive Therapeutics Inc		 0.01 0.21% 4.72 - - 11.89 14.15 9.85 -1.8103
ZTS
Zoetis Inc		 -2.82 3.58% 75.89 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 -0.19 0.62% 30.56 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 157.12 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 - -% 42.94 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Aquestive Therapeutics Inc

30 Technology Drive, Warren, NJ, United States, 07059

Key Executives

Name Title Year Born
Mr. Daniel Barber CEO, Pres & Director 1976
Mr. A. Ernest Toth Jr. Sr. VP & CFO 1959
Mr. Keith J. Kendall Consultant 1958
Mr. Alexander Mark Schobel Chief Innovation & Technology Officer 1959
Ms. Lori J. Braender BSBA, Esq., J.D. Sr. VP & Gen. Counsel 1956
Dr. Eric Dadey Ph.D. Sr. Vice-Pres of R&D NA
Mr. Peter E. Boyd Sr. VP of Clinical Operations & Information Technology 1965
Mr. Kenneth W. Marshall Sr. VP & Chief Commercial Officer 1959
Dr. Kenneth Truitt M.D. Chief Medical Officer NA
Mr. Robert Charles Arnold VP of Fin., Controller & Assistant Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.